sweelin® Clinical Trial Results Published in Leading Journal, Food Chemistry, Confirming Blood Glucose Safety

sweelin® Clinical Trial Results Published in Leading Journal, Food Chemistry, Confirming Blood Glucose Safety

This world's first clinical study on sweet proteins, reflects the clinical relevance of Amai Protein's sweelin®. The double-blind, randomized, crossover clinical study confirmed that sweelin® does not affect blood glucose, insulin and GLP-1 levels...

Origin Agritech Co-Authors Plant Biotechnology Journal Study That Breaks the Long-Standing Trade-Off Between Early-Maturing and High-Yield Corn

Origin Agritech Co-Authors Plant Biotechnology Journal Study That Breaks the Long-Standing Trade-Off Between Early-Maturing and High-Yield Corn

Gene-Editing Strategy Targets the Regulatory Switches of a Key Corn Gene, Producing Corn That Flowers Up to Five Days Earlier With Yields Comparable to Standard Varieties — A Foundation for Origin's Next-Generation Hybrid Pipeline BEIJING, June 2,...

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase...

Three Papers Published Consecutively in Nature Energy: JinkoSolar's Breakthroughs in TOPCon/Perovskite Tandem Technology Receive Authoritative Recognition

Three Papers Published Consecutively in Nature Energy: JinkoSolar's Breakthroughs in TOPCon/Perovskite Tandem Technology Receive Authoritative Recognition

SHANGHAI, April 18, 2026 /PRNewswire/ -- JinkoSolar, the global leading PV and ESS supplier, recently published three research papers in succession within a single month in Nature Energy, one of the premier journals in the field of energy research....

2025 China & Global Development Reports Published in Hainan

2025 China & Global Development Reports Published in Hainan

HAIKOU, China, April 18, 2026 /PRNewswire/ -- A report from the Hainan International Media Center: In Haikou on April 16th, during the 6th China International Consumer Products Expo, a book launch event was held to celebrate the publication of the...

Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism

Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism

BEIJING, Feb. 5, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature that pinpoints the core functional circuit underlying Parkinson's...

Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications

Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications

HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM),...

Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology

Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology

SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab...

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to...

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of...

  • 1
  • 2
  • menu
    menu